Test Price
1,500 AED✅ Home Collection Available
Immunophenotyping by Flow Cytometry: Leukemia Diagnostic Panel & Plasma Cell Dyscrasias | 1500 AED | DNA Labs UAE
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% diagnostic sensitivity achieved via ISO 9001:2015 accredited flow cytometry processing (Cert: INT/EGQ/2509DA/3139).
- Premium Home Collection: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary post-test telephonic interpretation session with a DHA-licensed clinical pathologist.
- Direct Insurance Billing: WhatsApp pre-verification of coverage at +971 54 548 8731.
Test Overview & Methodology
This advanced immunophenotyping panel identifies abnormal hematopoietic cells associated with leukemias and plasma cell dyscrasias, utilizing multiparametric flow cytometry to characterize surface and cytoplasmic markers. Accurate subclassification directly guides targeted therapy decisions in compliance with DHA oncology protocols. The panel differentiates B-cell, T-cell, and myeloid lineages, enabling precise WHO classification for personalized treatment planning.
| Feature | Our Test (Premium Panel) | Closest Alternative (Standard Labs) |
|---|---|---|
| Methodology | Multiparametric Flow Cytometry (MFC) with advanced gating, ISO 15189 aligned | Basic 4-color flow cytometry, limited antibody panels |
| Report Turnaround | Same-day reporting if sample received by 9 AM | 2–5 working days, often outsourced |
| Diagnostic Sensitivity | 99.9% for minimal residual disease (MRD) detection | 85–92%, variable with operator experience |
| Pre-analytical Logistics | Cold-chain home collection at 18°C–22°C, no refrigeration | Ambient transport, frequent pre-analytical errors |
Physician Insight & Safety Protocols
"Flow cytometry immunophenotyping provides critical data for classifying hematologic malignancies, yet results must always be integrated with morphology, cytogenetics, and clinical presentation. A positive finding does not automatically indicate active disease; careful correlation with the patient's history and ancillary studies is essential. Every report should be discussed with a hematologist-oncologist to formulate a comprehensive management strategy." — Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011.
Advisory & Medication Guidance
Medication Alert: Do not discontinue or modify any prescribed medication without consulting your physician. This test does not replace ongoing hematological monitoring.
Safety Exclusion Criteria & Emergency Red Flags
- Severe bleeding disorders (e.g., hemophilia A/B with factor deficiency <1%) — bone marrow aspiration contraindicated.
- Active infection at phlebotomy or bone marrow site.
- Known allergy to local anesthetics used in aspiration; premedication required.
- If you experience: uncontrolled bleeding, high fever (>38.5°C), or severe pain after sample collection, seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What conditions does this leukemia and plasma cell dyscrasia panel detect?
This panel identifies acute and chronic leukemias, multiple myeloma, and related plasma cell disorders by detecting aberrant antigen expression. It differentiates B-cell, T-cell, and myeloid lineages, enabling precise WHO classification and guiding targeted therapy decisions.
2. How should I prepare for the test and what sample type is required?
No fasting is needed; simply provide your complete clinical history and continue prescribed medications unless otherwise directed. We collect 3 mL whole blood in EDTA and sodium heparin tubes. Samples must be transported immediately at 18°C–22°C — never refrigerated or frozen. Our VIP Mobile Phlebotomy service handles collection at your convenience.
3. When will I receive my results and how are they verified?
Results are reported the same day if your sample reaches our laboratory by 9 AM, following dual-pathologist verification. Every report includes a clinical correlation note and is accessible via secure patient portal.
UAE Regulatory & Data Privacy Adherence
- Licensed under DHA Facility License 1143; all procedures comply with Federal Decree-Law No. 4 of 2016 on Medical Liability for clinical testing safety and patient consent.
- Data security and privacy are governed by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- ISO 9001:2015 Certified (INT/EGQ/2509DA/3139) — guaranteeing quality management in every step.
- No identifiable patient information is shared without explicit consent.
Clinical & Logistical Metadata
| Test Name | Immunophenotyping by Flow Cytometry: Leukemia Diagnostic Panel & Plasma Cell Dyscrasias |
| Price (AED) | 1500 |
| Turnaround Time | Same-day reporting if sample received by 9 AM |
| Sample Type / Matrix | Peripheral Whole Blood (3 mL in EDTA and sodium heparin tubes) |
| Methodology Used | Multiparametric Flow Cytometry (MFC) with advanced gating |
| ICD-10-CM Code | C95.9, C91.0, C92.0, C90.0 |
| LOINC Code | 48508-3 |
| DHA Facility License & Address | License 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians